Urinary excretion rates of 6-keto-PGF1 alpha in preterm infants recovering from respiratory distress with and without patent ductus arteriosus

Pediatr Res. 1984 Jun;18(6):520-4. doi: 10.1203/00006450-198406000-00007.


Patency of the ductus arteriosus in preterm infants is mediated by vasodilating prostanoids; however, reliable methods to monitor prostanoid activity or production in preterm infants are lacking. We measured the excretion rates of major and characteristic urinary metabolites of prostacyclin (PGI2), PGE1, and PGE2, 6-keto-PGF1 alpha, and 7 alpha-hydroxy-5,11-diketotetranorprostane-1,16-dioic acid (PGE-M), respectively. Besides these parameters which reflect total body prostanoid turnover and production, the urinary levels of PGE2 and PGF2 alpha, the primary prostaglandins, were measured as an index of renal prostanoid synthesis. There were four study groups. One contained 11 thriving preterm infants; a second, six preterm infants with respiratory distress syndrome (RDS); a third, 30 preterm infants with RDS and patent ductus arteriosus (PDA); and a fourth, nine fullterm infants. All infants with RDS required artificial ventilation. There were no significant differences in PGE-M, PGE2, and PGF2 alpha excretion rates among the various groups; however, a significant increase of the 6-keto-PGF1 alpha excretion rates was observed in the groups of infants with RDS and with and without PDA (P less than 0.01 and P less than 0.02, respectively). Spontaneous (n = 2) or indomethacin-induced (n = 6) closure of PDA was associated with weaning from the respirator and a concomitant drop into the normal and subnormal range of the excretion rates of 6-keto-PGF1 alpha (P less than 0.01) and PGE-M (P less than 0.02).

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 6-Ketoprostaglandin F1 alpha / urine*
  • Alprostadil
  • Dinoprost
  • Dinoprostone
  • Ductus Arteriosus, Patent / complications
  • Ductus Arteriosus, Patent / drug therapy
  • Ductus Arteriosus, Patent / urine*
  • Female
  • Humans
  • Indomethacin / therapeutic use
  • Infant, Newborn
  • Male
  • Prostaglandins E / metabolism
  • Prostaglandins E / urine
  • Prostaglandins F / urine
  • Prostanoic Acids / urine
  • Respiration, Artificial
  • Respiratory Distress Syndrome, Newborn / complications
  • Respiratory Distress Syndrome, Newborn / urine*


  • 7 alpha-hydroxy-5,11-diketotetranorprostane-1,16-dioic acid
  • Prostaglandins E
  • Prostaglandins F
  • Prostanoic Acids
  • 6-Ketoprostaglandin F1 alpha
  • Dinoprost
  • Alprostadil
  • Dinoprostone
  • Indomethacin